Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD8+MTs+ Effector T Cells from Enlarged Tumor-Draining Lymph Nodes Drive Enhanced Tumor Immunogenicity and Improved Prognosis in Colorectal Cancer Patients

ABSTRACT: CD8+MTs+ Effector T Cells from Enlarged Tumor-Draining Lymph Nodes Drive Enhanced Tumor Immunogenicity and Improved Prognosis in Colorectal Cancer Patients

PROVIDER: PRJNA1189105 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31671321_1.fastq.gz	Fastqsanger.gz
	SRR31671321_2.fastq.gz	Fastqsanger.gz
	SRR31671322_1.fastq.gz	Fastqsanger.gz
	SRR31671322_2.fastq.gz	Fastqsanger.gz
	SRR31671323_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 42

Similar Datasets

CD8+MTs+ Effector T Cells from Enlarged Tumor-Draining Lymph Nodes Drive Enhanced Tumor Immunogenicity and Improved Prognosis in Colorectal Cancer Patients

Project description:Tumor-draining lymph nodes (TDLNs) play a crucial role in anti-tumor immunity. However, the heterogeneity of TDLNs significantly impacts their immune function. We employed single-cell RNA sequencing to dissect the immune landscape of TDLNs of colorectal cancer (CRC), revealing that enlarged non-metastatic TDLNs (L-TDLNs) are enriched with CD8+ effector T cells (Teff) exhibiting a distinct metallothionein (MT)-positive signature. These CD8+MTs+ Teff cells, characterized by heightened cytotoxicity and a stress-adapted phenotype, are critical mediators of anti-tumor immunity. Our data indicate that these cells migrate from L-TDLNs to tumor sites, enhancing tumor immunogenicity. Moreover, CRC patients with a high level of CD8+MTs+ Teff in tumor site showed a significant survival advantage, particularly when treated with adjuvant chemotherapy. These findings underscore the importance of L-TDLNs in shaping effective antitumor immune responses in CRC, suggesting that the CD8+MTs+ Teff cell population may serve as a novel prognostic biomarker and therapeutic target. Our study provides a comprehensive framework for understanding the cellular dynamics within TDLNs and their impact on CRC progression and treatment response.

2024-11-26 | GSE282542 | GEO

Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

Project description:Metabolic alteration influences cancer immunity. However, the role and mechanism of metabolic adaption on immune checkpoint blockade (ICB) responses remains ill-defined. Here, metabolomic profiling in mouse tumor models and cancer patients treated with ICB was performed. We found that metabolite inosine was associated with ICB sensitivity in mice and humans, and overcame ICB resistance in several mouse tumor models. Notably, inosine sensitized tumor cells to T cell-mediated cytotoxicity by amplifying tumor-intrinsic immunogenicity. Chemical proteomics further identified that inosine directly bound and inhibited ubiquitin-activating enzyme UBA6. Tumor intrinsic UBA6 loss augmented tumor immunogenicity and substituted the synergistic effect of inosine in combination with ICB. Clinically, tumor UBA6 expression negatively correlated with ICB response in cancer patients. Thus, we reveal an unappreciated function of inosine on tumor-intrinsic immunogenicity and UBA6 as a candidate target for immunotherapy.

2022-08-04 | GSE210225 | GEO

Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming

Project description:Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming

| PRJNA933158 | ENA

Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

Project description:Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

| PRJNA864795 | ENA

Discovery of genes differentially-expressed in the endothelium of lymph nodes draining metastatic versus non-metastatic tumors

Project description:Metastasis to lymph nodes is an early and prognostically important event in the progression of many human cancers, and is associated with expression of vascular endothelial growth factor-D (VEGF-D). Changes to lymph node vasculature occur during metastasis, and may establish a metastatic niche capable of attracting and supporting tumor cells. We used microarrays to characterise the molecular profiles of endothelial cells from lymph nodes draining metastatic (VEGF-D-overexpressing) and non-metastatic tumors, and to identify differentially-expressed genes that might have therapeutic or prognostic potential. Draining lymph nodes of metastatic (VEGF-D-overexpressing) or non-metastatic tumors were pooled from 1-5 mice and enzymatically digested. Lymph nodes draining metastatic tumors were included for the analysis only if macroscopically enlarged, indicating the presence of metastatic cells. After digestion, tumor cells and leukocytes were depleted via immunomagnetic selection, and the resulting lymph node stromal cells were cultured briefly. Podoplanin was then used as a positive immunomagnetic selection marker to enrich for lymphatic and other endothelial cells in the lymph node. RNA was isolated from biological duplicate lymph node endothelial cell (LN EC) preparations and analysed by microarray.

2011-09-22 | E-GEOD-31123 | biostudies-arrayexpress

Transcriptional remodeling of lymphatic endothelial cells from tumor-draining lymph nodes in melanoma

Project description:We investigated transcriptional changes in lymphatic endothelial cells lining tumor-draining lymph nodes in melanoma using single-cell RNA sequencing.

2022-10-18 | E-MTAB-11524 | biostudies-arrayexpress

Mouse tumors: Chaos3 Mammary Tumors (MTs) vs. Controls

Project description:CNV profiling of tumors obtained from our Chaos3 mouse model for spontaneous breast cancer. The goal of this experiment was to determine copy number variations that were specific to MTs derived from this mouse model, when comapared to non-MTs.

2016-09-14 | GSE81967 | GEO

WGS Blindness enlarged globe chicken

Project description:WGS Blindness enlarged globe chicken

| PRJEB15670 | ENA

Gene expression signatures for murine B cells from tumor-draining lymph nodes

Project description:To determine the influence of primary tumors on pre-metastatic lymph nodes, we have employed whole genome microarray expression profiling as a discovery platform to identify gene signatures of B cells from tumor-draining lymph nodes, compared with normal lymph nodes. We subcutaneously inoculated C57BL/6 mice with the 4T1 mammary carcinoma. Two weeks later, tumor-draining lymph nodes were dissociated and B cells (CD19+) were sorted. Lymph nodes B cells from normal mice without tumor bearing were set as controls.

2018-04-18 | GSE113250 | GEO

Gene expression signatures for murine stromal cells from tumor-draining lymph nodes

Project description:To determine the influence of primary tumors on pre-metastatic lymph nodes, we have employed whole genome microarray expression profiling as a discovery platform to identify gene signatures of stromal cells from tumor-draining lymph nodes, compared with normal lymph nodes. We subcutaneously inoculated C57BL/6 mice with the 4T1 mammary carcinoma. Two weeks later, tumor-draining lymph nodes were dissociated and stromal cells (CD45-) were sorted. Lymph nodes stromal cells from normal mice without tumor bearing were set as controls.

2018-04-18 | GSE113249 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data